Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis

KATSUNORI SUZUKI, KAZUYOSHI SAITO, SHIZUYO TSUJIMURA, SHINGO NAKAYAMADA, KUNIHIRO YAMAOKA, NORIFUMI SAWAMUKAI, SHIGERU IWATA, MASAO NAWATA, KAZUHISA NAKANO and YOSHIYA TANAKA

J Rheumatol 2010;37;512-520
http://www.jrheum.org/content/37/3/512

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis

KATSUNORI SUZUKI, KAZUYOSHI SAITO, SHIZUYO TSUJIMURA, SHINGO NAKAYAMADA, KUNIHIRO YAMAOKA, NORIFUMI SAWAMUKAI, SHIGERU IWATA, MASAO NAWATA, KAZUHISA NAKANO, and YOSHIYATANAKA

ABSTRACT. Objective. Tacrolimus, a calcineurin inhibitor, is used for treatment of rheumatoid arthritis (RA). It also inhibits functions of P-glycoprotein, which is involved in drug resistance. We examined the mechanisms of early response to 2-week tacrolimus treatment in patients with RA.

Methods. One hundred thirteen patients with refractory RA despite at least 3 antirheumatic agents, including methotrexate, were treated with tacrolimus (1.5–3 mg/day) and the response was assessed at 2 weeks. Expression of the multidrug resistance (MDR-1) gene and P-glycoprotein was assessed in peripheral blood mononuclear cells (PBMC) collected from 113 patients and 40 healthy subjects. The drug exclusion function by the P-glycoprotein was measured by the residual amount of intracellular tritium-labeled dexamethasone cell/medium ratio (C/M ratio).

Results. The disease activity of enrolled patients was 5.8 ± 1.2 (mean ± SD) by DAS28 erythrocyte sedimentation rate. A good response to tacrolimus was noted at 2 weeks in 22 of 113 patients. At baseline, PBMC of patients with RA showed upregulated expression of MDR-1 gene and P-glycoprotein and low C/M ratio. The response to tacrolimus correlated with P-glycoprotein expression and C/M ratio. A significant improvement in C/M ratio was noted after 2 weeks of treatment. The C/M ratio correlated significantly with P-glycoprotein expression on CD4+ lymphocytes.

Conclusion. Early efficacy of tacrolimus treatment depended on its inhibitory effect on the drug exclusion function of P-glycoprotein, leading to restoration of intracellular therapeutic levels of corticosteroids and clinical improvement. Evaluation of P-glycoprotein expression only lymphocytes is potentially useful for predicting the response to RA treatment. (First Release Jan 15 2010; JRheumatol 2010;37:512–20; doi:10.3899/jrheum.090048)

Key Indexing Terms: P-GLYCOPEPTIDE RHEUMATOID ARTHRITIS DRUG RESISTANCE TACROLIMUS CALCINEURIN INHIBITOR

Rheumatoid arthritis (RA) is a systemic disease characterized pathologically by the presence of autoreactive lymphocytes and clinically by tenderness and swelling of multiple joints. Treatment of RA includes the use of antirheumatic drugs designed to correct the autoreactive lymphocytes. However, some patients respond poorly to such drugs or develop resistance to them after an initial response.

Drug resistance is partly caused by disturbance of the drug exclusion pump of P-glycoprotein on the surface of tumor cells. P-glycoprotein is induced by transcription factor YB-1, which is activated by various external stimuli such as drugs and inflammatory cytokines and is expressed on cells following the induction of multidrug resistance gene (MDR-1).

We have reported the expression of P-glycoprotein in lymphocytes and that its expression pathway is similar to that of drug exclusion. The transcription factor YB-1 is expressed in the cytoplasm of peripheral blood lymphocytes of healthy subjects. Absence of MDR-1 gene expression is associated with weak or no P-glycoprotein expression. Thus, in peripheral blood lymphocytes of patients with RA, stimuli from inflammatory cytokines, such as interleukin 2...
MATERIALS AND METHODS

**Materials.**

**Patients.** The subjects were 113 patients with RA who met the diagnostic criteria of the American College of Rheumatology and showed resistance to antirheumatic agents. In addition, the study included peripheral blood samples from 40 healthy adults, matched by age and sex to the patients with RA. The control subjects were either staff members of our hospital or samples from healthy subjects who visited our hospital for medical examinations.

**Diagnosis.** Patients with RA that was resistant to treatment were defined as patients with a Disease Activity Score (DAS28) erythrocyte sedimentation rate (ESR) score > 3.1 for RA activity despite receiving treatment with adequate doses of at least 3 antirheumatic drugs, including methotrexate (MTX), for a minimum of 3 months, and showing no or moderate response, according to the European League Against Rheumatism (EULAR) improvement criteria. Tacrolimus was used for these patients with treatment-resistant RA. Tacrolimus was administered at a daily dose of 3 mg in patients ≤ 65 years of age and 1.5 mg for those aged ≥ 65 years. All other antirheumatic drugs used by the enrolled patients were withheld during our 4-week study, except for nonsteroidal anti-inflammatory drugs and corticosteroids. One patient who underwent treatment by biological disease-modifying antirheumatic drugs was not included in our study.

**Tacrolimus.** We started tacrolimus at the hospital of the University of Occupational and Environmental Health, Japan. The same person evaluated the clinical efficacy of tacrolimus throughout the observation period. The expression of P-glycoprotein on lymphocytes and polymerase chain reaction (PCR) analysis of the MDR-1 gene were conducted by an individual different from the one who evaluated the clinical effects such as the number of swollen and tender joints, and evaluation by visual analog scale. Data analysis was performed by a third individual blinded to the other 2 investigators.

**Measurement.** The background factors investigated were sex, age, duration of RA, dosage of antirheumatic drugs including corticosteroids, history of treatment, use of concomitant drugs such as corticosteroids at the time of initiation of tacrolimus therapy, and the dosage of other drugs.

**Results.** We also evaluated the severity of morning stiffness, number of swollen joints, number of tender joints, and patient-evaluated pain and overall evaluation by a visual analog scale, in addition to evaluation by the attending physician. The response to treatment was evaluated using the EULAR criteria.

**Expression of P-glycoprotein on peripheral blood mononuclear cells.** Peripheral blood mononuclear cells (PBMC) were separated by specific gravity fractionation using Lymphocyte Separation Medium 50494 (Pharmacia Biotech, Uppsala, Sweden). Of the CD antigens that were expressed on PBMC, ≥ 90% were on lymphocytes (CD4, CD8, or CD19+ cells) and ≥ 10% were on mononuclear cells. PBMC were stained and analyzed by flow cytometry using the standard procedure of FACScan (Becton Dickinson, Mountain View, CA, USA) as described. The cells were divided to a final concentration of 2 × 10^5 cells/well. Polyclonal γ-globulin (10 µg/ml; Mitsubishi Welpharma Co., Osaka, Japan) was added to the culture to block Fc receptors. After culture, MRK-16 (100 µg/ml; Kyowa Medex, Tokyo, Japan), a monoclonal antibody specific for P-glycoprotein, was added to the culture solution. The cells were further labeled with FITC-conjugated antimouse IgG antibody (5 µg/ml; Fujisawa, Osaka, Japan). For cell staining, cells were treated with antimouse IgG that binds to nonspecific sites before using phycoerythrin-conjugated CD4 mAb or CD19 mAb (1.25 µg/ml; Becton Dickinson). Of these double-stained cells, target cells that were gated based on CD4 or CD19 expression were extracted using FACScan. Quantification of the cell surface antigens on 1 cell was performed using QIFIKIT beads (Dako, Kyoto, Japan) as reported. The data were used to construct a calibration curve of the mean fluorescence intensity versus antibody-binding capacity. The cell specimen was analyzed on the FACScan and the antibody-binding capacity calculated by interpolation on the calibration curve. When the green-fluorescence laser detection was set at 500 nm in the FACScan, the antibody-binding capacity was equal to 202.98 × exp (0.0092 × mean fluorescence intensity) (R^2 = 0.9995). Subsequently, the specific antibody-binding capacity was obtained after correcting for the background and apparent antibody-binding capacity of the negative control antimouse IgG antibody. The specific antibody-binding capacity represented the mean number of accessible antigenic sites per cell, referred to as antigen density and expressed in sites/cell. The cell number ratio (C/M ratio) of dexamethasone. To assess the function of P-glycoprotein, PBMC were collected from patients with RA and analyzed for the residual amounts of carbon-labeled butanol and tritium-labeled dexamethasone in cells. The C/M ratio represented the coefficient of intracellular and extracellular ratio of dexamethasone and was determined using the formula:

\[
\text{C/M ratio} = \left(\frac{\text{[^{3}H] in cell fraction}}{\text{[^{14}C] in cell fraction}}\right) \\
\left(\frac{\text{[^{14}C] in medium fraction}}{\text{[^{3}H] in medium fraction}}\right)
\]

Changes in the residual amount of the drug in PBMC of patients with RA were assessed by pretreatment of the cells with tacrolimus 0–50 ng/ml, sulfasalazine (SSZ) 0–50 µg/ml, or MTX 0–400 ng/ml. Carbon-labeled n-butanol (1.61 mCi/mmol; Toho Biomedical, Tokyo, Japan)
Japan) was diluted with 0.5 MBq/ml of non-carbon-labeled butanol (Sigma Aldrich, Tokyo, Japan). Tritium-labeled dexamethasone (40.0 Ci/mmol; Perkin Elmer, Boston, MA, USA) was dissolved in dimethyl sulfoxide (DMSO; Nacalai Tesque Inc., Tokyo, Japan) and diluted with phosphate-buffered saline (PBS; adjusted to a final concentration of DMSO of 0.1%).

To supply ATP, 7 mM of dextrose was added to PBS. PBMC were suspended in this solution and adjusted so that the cell density was 5 × 10⁶ cells/ml. PBMC were cultured at 37°C for 20 min in 5 × 10⁻⁵ M of carbon-labeled butanol and 3.0 × 10⁻⁸ M of tritium-labeled dexamethasone. After the culture, 100 μl aliquots of the cells were layered in 80 μl of a mixture of lauryl bromide and silicone oil (2:1 ratio; Nacalai Tesque) in an Eppendorf tube (Assist, Tokyo, Japan). After centrifugation at 10,000 rpm for 2 min, the tube was instantly frozen in liquid nitrogen. The frozen tube was divided into medium (upper layer) and mixture (cell components, bottom layer) bound parts. Solutecne-350 and 10 ml Hionic-Flouor (Packard, Meriden, CT, USA) were added to the cell components. The medium part was dissolved in a mixture of toluene (Wako Pure Chemicals, Osaka, Japan), methanol (Wako), ethylene glycol monoethanol (Nacalai Tesque), and Permaflour (ratio 200:50:50:12; Packard). Both parts were irradiated using a scintillation counter.

**Reverse transcription-PCR.** Whole-cell RNA was obtained from PBMC of healthy adults and patients with RA and separated using the Isogen (Wako) protocol. Total RNA (500 ng) was reverse transcribed for 30 min at 42°C. Denaturing was performed for 45 s by iCyler (Bio-Rad, Richmond, CA, USA). Amplification was performed with annealing at 55°C for 45 s and extension at 72°C for 90 s using the 30-cycle specific MDR-1 and β-actin primers. The sequences of the primers are human β-actin forward, 5'-TGAACC CCAAGG CCAACC GC-3', reverse, 5'-TTGGT TGCTG TGG GTG CCA GGG CA-3'; and human MDR-1 forward, 5'-CCC ATC ATT GCA ATA GCG GGG-3', reverse, 5'-GTT CAA ACT TCT GCT GCT GA-3'. Amplified products were electrophoresed with Marker 4 (Nippon Gene, Tokyo, Japan) on 3% agarose gels.

**Statistical analysis.** Continuous variables related to patients’ background factors are presented as mean ± standard deviation. Differences between 2 groups were tested statistically by Wilcoxon test.

Correlations between background factors and response to treatment at Week 2 were analyzed by Pearson’s correlation coefficient. Multivariate logistic analysis was also performed. A 2-tailed p value ≤ 0.05 was considered statistically significant. All statistical analyses were performed using JMP software, version 7.0 (SAS Institute Inc, Cary, NC, USA) on Mac OSX.

**RESULTS**

A total of 113 patients with RA were treated with tacrolimus. The mean age of the population was 65.5 ± 12.2 years (median 66 yrs), mean disease duration was 114 ± 120 months (median 96 mo), the ratio of men to women was 23:90, the mean dose of corticosteroid was 2.69 ± 3.69 mg/day, and the rate of concomitant treatment with corticosteroid was 56%.

The mean DAS28-ESR of the enrolled patients with RA at the time of initiation of tacrolimus treatment was 5.8 ± 1.2 (median 5.9) and the percentage of patients with a high DAS28-ESR disease activity score (≥ 5.1) was 83% (Figure 1A). However, the percentage of patients with a DAS28-ESR disease activity score < 3.2, categorized as low disease activity, increased from 0% at baseline to 23% after 2 weeks of the tacrolimus therapy. The percentages of patients with a good response, moderate response, and no response were 19%, 34%, and 47%, respectively, according to the improve-

**EULAR** (Figure 1B). In general, the clinical efficacy of tacrolimus, mediated through inhibition of calcineurin, becomes evident after more than 1 month of therapy. However, in our study, about 20% of the patients showed marked response at 2 weeks after the start of treatment. The effects lasted for 12 weeks after tacrolimus treatment and DAS28 gradually decreased, and the proportion of patients who achieved more than moderate response also increased.

Next, we investigated the mechanism of the marked response to 2-week tacrolimus treatment. To examine the possibility that the early efficacy was due to the inhibitory effect of tacrolimus on P-glycoprotein, we analyzed P-glycoprotein expression on lymphocytes and drug exclusion by P-glycoprotein using the C/M ratio. P-glycoprotein was overexpressed in CD4 and CD19 lymphocytes of patients with RA, compared with the healthy controls (Figure 2A). The MDR-1 gene was not expressed in the lymphocytes of healthy controls. In contrast, even with no stimulation, the MDR-1 gene was clearly expressed (Figure 2B) in lymphocytes of all of 5 representative patients with RA (patients 1–3 had good response and 4 and 5 had moderate response).

We also measured intracellular concentrations of tritium-labeled dexamethasone in vitro. In healthy adult lymphocytes that do not express P-glycoprotein, the C/M ratio increased in a time-dependent manner. In contrast, there was no increase in C/M ratio in P-glycoprotein-expressing lymphocytes of patients with RA (Figure 3A). The addition of tacrolimus at 0–50 ng/ml, which has an inhibitory effect on P-glycoprotein, increased the C/M ratio in a dose-dependent manner (Figure 3B). However, the addition of MTX or SSZ as the control drug did not result in any significant change in the C/M ratio (Figure 3B).

Next, we analyzed the relationships among various background factors and the response to tacrolimus treatment (Table 1). The response to such treatment was not influenced by factors related to RA disease activity, including number of swollen joints, number of tender joints, visual analog scale, CRP, and ESR. Further, the response to tacrolimus treatment did not correlate with age, sex, duration of illness, mean corticosteroid dose, and tacrolimus dose. On the other hand, the rate of concomitant use of corticosteroids was significantly different among nonresponders (32/53; 60.4%), moderate responders (18/38; 47.4%), and good responders (22/22; 100%), as shown in Table 1. The percentage of patients using corticosteroids who did not achieve good response to tacrolimus (53.9%) was significantly lower than that of patients who did.

We also analyzed the correlation between response to treatment and P-glycoprotein expression and C/M ratio (Table 1). In this analysis, P-glycoprotein expression on CD4- and CD19+ lymphocytes was stratified by the response to treatment. The expression levels of P-glycoprotein in both CD4- and CD19+ lymphocytes were signifi-

---

*Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.*
**Figure 1.** Changes in disease activity and treatment response at baseline (before induction of tacrolimus treatment) and at 2 and 12 weeks of treatment in patients with treatment-resistant RA. RA disease activity was assessed by DAS28-ESR. Treatment response was assessed using EULAR criteria. A. Disease activity. Data for individual patients and mean ± SD values for baseline and posttreatment for the groups. *p < 0.05, Wilcoxon test. B. Treatment response at 2 and 12 weeks after commencement of tacrolimus treatment.

**Figure 2.** P-glycoprotein expression on lymphocytes of patients with RA treated with tacrolimus and healthy controls. A. Mononuclear cells were isolated from peripheral blood of patients with treatment-resistant RA and controls and stained with CD4 and CD19 antibodies and P-glycoprotein antibodies. Expression of P-glycoprotein on lymphocyte was measured. Data for individual subjects and mean ± SD values of the 2 groups are shown. **p < 0.01, Wilcoxon test. B. Multidrug resistance gene (MDR-1) was assessed by RT-PCR. Note the expression of MDR-1 in patients with treatment-resistant RA but not in healthy controls. Representative results of 5 experiments with similar results. Electrophoresis was performed on the amplifier together with Marker 4 in 3% agarose gel.
significantly higher in the good response group compared with the other groups (no response and moderate response; Table 1, Figure 4A). Moreover, the C/M ratio was significantly lower in the good response group compared with the moderate or no response group. Interestingly, the C/M ratio before the initiation of tacrolimus treatment was significantly lower in the good response group compared with the moderate and no response groups (Figure 4B). However, at 2 weeks after the initiation of tacrolimus treatment, the value improved significantly in the good response group compared with the moderate and no response groups (Figure 4C). In addition, P-glycoprotein expression at 2 weeks after initiation of tacrolimus therapy was similar to that at baseline (before therapy; Figure 4D).

Finally, multivariate logistic regression analysis was used to determine those factors that can explain the response to tacrolimus treatment. The analysis included the C/M ratio, P-glycoprotein expression on CD4+ lymphocytes, CRP, and morning stiffness. Multivariate logistic regression analysis identified the C/M ratio and P-glycoprotein expression on CD4+ lymphocytes as significant and independent determinants of a good response to tacrolimus treatment (Table 2).

DISCUSSION
The safety and efficacy of tacrolimus in the treatment of RA is currently under investigation. The response of patients with RA to tacrolimus treatment is normally investigated about 1–2 months after initiation of such treatment. In our study, however, we noted that some patients responded...
markedly well to tacrolimus treatment after only 2 weeks. In order to explain this early response to treatment, we investigated the inhibitory effect of tacrolimus on P-glycoprotein, both in vitro and in vivo. PBMC of patients with RA showed expression of the MDR-1 gene, and overexpression of P-glycoprotein on the lymphocyte surface. These features were not identified in PBMC from healthy adults. Further, the C/M ratio in patients with RA was lower than that of the healthy adults, indicating enhanced drug exclusion function of P-glycoprotein. However, in in vitro experiments, the addition of tacrolimus to PBMC improved the C/M ratio to a level similar to that of healthy adults, and the response depended on the dose of tacrolimus added to the cell culture. We also tested the response of PBMC to 0–50 g/ml SSZ and 0–400 ng/ml MTX. These doses represent the C_{max} values used clinically. At these concentrations, SSZ and MTX, which do not inhibit P-glycoprotein, did not improve the C/M ratio. These findings indicate that the improvement in C/M ratio is not due to a secondary inhibition of P-glycoprotein through inhibition of lymphocyte activation. The results of in vitro experiments were confirmed in vivo; tacrolimus produced a significant increase in the C/M ratio of patients who showed a good response to 2-week tacrolimus therapy (based on the improvement criteria of EULAR). Multivariate logistic analysis indicated that after 2 weeks of tacrolimus treatment, overexpression of P-glycoprotein on lymphocytes in the good response group correlated significantly with a low C/M ratio before treatment. Since all patients were also treated with corticosteroids throughout the study, the above findings suggest that the early response to tacrolimus therapy was not due to tacrolimus alone but also to inhibition of extracellular exclusion of corticosteroids, mediated by the inhibitory effect of tacrolimus on P-glycoprotein expression. In addition, there were no differences in P-glycoprotein expression between initiation and 2 weeks after initiation of tacrolimus (Figure 4D). Therefore, the main effect of tacrolimus was due, not to a decrease in P-glycoprotein molecules on lymphocytes, but to functional competitive inhibition of drug exclusion.

Humoral factors such as TNF-α, IL-6, and IL-1 that are locally produced in joints, or upregulation of P-glycoprotein expression through induction of transcription of MDR-1 gene following activation of YB-1 by certain drugs that are added to the treatment for RA such as antirheumatic drugs and corticosteroids, are involved in the development of resistance to treatment in patients with RA. Often, the same drug must be used continuously over a long period to control RA disease activity. During this period, expression of the multidrug resistance genes may be induced due to increased disease activity, resulting in drug resistance. For example, increased disease activity and low response rate following long-term use have been reported during treatment with SSZ. In fact, upregulation of P-glycoprotein expression was reported in low responders to SSZ. With SSZ, which is used in the treatment of RA, stimulation of cells that enhance P-glycoprotein expression causes simultaneous extracellular exclusion of the drug. Thus, the low response to SSZ is probably due to increased extracellular exclusion of the drug through P-glycoprotein. The above finding of the inhibitory effect of tacrolimus on P-glycoprotein expression suggests that tacrolimus could potentially improve the resistance to other drugs in addition to corticosteroids.

We demonstrated that tacrolimus inhibits drug exclusion mechanisms operating through P-glycoprotein in patients with good response after 2 weeks of treatment. As a drug used for management of treatment-resistant RA, tacrolimus

Table 1. Baseline clinical characteristics of patients with RA treated with tacrolimus. P value represents differences between good response and moderate and no response groups.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No Response (n = 53)</th>
<th>Moderate Response (n = 38)</th>
<th>Good Response (n = 22)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>65.1 ± 12.7</td>
<td>66.2 ± 15.3</td>
<td>68.0 ± 12.2</td>
<td>NS</td>
</tr>
<tr>
<td>Disease duration (mo)</td>
<td>166 ± 143</td>
<td>115 ± 108</td>
<td>171 ± 157</td>
<td>NS</td>
</tr>
<tr>
<td>Morning stiffness (min)</td>
<td>278 ± 369</td>
<td>171 ± 323</td>
<td>195 ± 413</td>
<td>NS</td>
</tr>
<tr>
<td>No. of tender joints</td>
<td>10.2 ± 6.1</td>
<td>8.6 ± 4.6</td>
<td>9.9 ± 8.2</td>
<td>NS</td>
</tr>
<tr>
<td>No. of swollen joints</td>
<td>9.0 ± 4.3</td>
<td>7.3 ± 4.8</td>
<td>7.0 ± 3.9</td>
<td>NS</td>
</tr>
<tr>
<td>Visual analog scale (mm)</td>
<td>56.5 ± 18.6</td>
<td>66.5 ± 21.0</td>
<td>54.6 ± 24.5</td>
<td>NS</td>
</tr>
<tr>
<td>C-reactive protein (mg/dl)</td>
<td>2.8 ± 2.6</td>
<td>1.5 ± 1.6</td>
<td>2.2 ± 2.6</td>
<td>NS</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (ESR, mm/h)</td>
<td>60 ± 29</td>
<td>48 ± 26</td>
<td>42 ± 32</td>
<td>NS</td>
</tr>
<tr>
<td>Rheumatoid factor (IU/l)</td>
<td>275 ± 341</td>
<td>423 ± 1103</td>
<td>68 ± 63</td>
<td>NS</td>
</tr>
<tr>
<td>Matrix metalloproteinase</td>
<td>296 ± 302</td>
<td>302 ± 371</td>
<td>192 ± 139</td>
<td>NS</td>
</tr>
<tr>
<td>Disease activity 28 ESR</td>
<td>5.8 ± 0.7</td>
<td>5.7 ± 0.8</td>
<td>5.3 ± 0.9</td>
<td>NS</td>
</tr>
<tr>
<td>Prednisone (mg)</td>
<td>1.3 ± 2.6</td>
<td>1.5 ± 3.8</td>
<td>2.9 ± 2.7</td>
<td>NS</td>
</tr>
<tr>
<td>Patients on prednisone (%)</td>
<td>60.4 (32/53)</td>
<td>47.4 (18/38)</td>
<td>100 (22/22)</td>
<td>0.05</td>
</tr>
<tr>
<td>Tacrolimus (mg)</td>
<td>2.1 ± 0.8</td>
<td>2.0 ± 0.8</td>
<td>1.9 ± 0.8</td>
<td>NS</td>
</tr>
<tr>
<td>P-glycoprotein expression on CD4 (molecule/cell)</td>
<td>140 ± 58</td>
<td>159 ± 65</td>
<td>248 ± 110</td>
<td>0.05</td>
</tr>
<tr>
<td>P-glycoprotein expression on CD19 (molecule/cell)</td>
<td>374 ± 171</td>
<td>388 ± 173</td>
<td>586 ± 193</td>
<td>0.05</td>
</tr>
<tr>
<td>C/M ratio</td>
<td>0.49 ± 0.12</td>
<td>0.49 ± 0.17</td>
<td>0.36 ± 0.12</td>
<td>0.01</td>
</tr>
</tbody>
</table>

C/M: cell/medium. NS: nonsignificant.
inhibits disease activity by blocking the calcineurin pathway and improves the low response by inhibiting drug exclusion of concomitantly used drugs through P-glycoprotein. Thus, among the existing antirheumatic drugs, tacrolimus is a potentially useful drug, although its mechanism of action is unknown. Patients on combination treatment have high expression levels of P-glycoprotein and low C/M ratio before the initiation of tacrolimus treatment because the concomitantly used drug, such as a corticosteroid, becomes a substrate for P-glycoprotein. Thus, in such patients, treatment with tacrolimus is expected to result in an increase in intracellular concentration of corticosteroids through the inhibitory effect of tacrolimus on P-glycoprotein, leading to a rapid remanifestation of the clinical efficacy of corticosteroid and thus early efficacy. In other words, it is likely that tacrolimus, through its inhibitory action on P-glycoprotein, can lower treatment resistance due to extracellular exclusion of drugs such as corticosteroids and SSZ, leading to improved response to treatment. Our results suggest that initiation of tacrolimus treatment for such patients is highly useful clinically. In addition, the determination of P-glycoprotein expression level on lymphocytes, which correlates with clinical response, is useful for predicting the response to treatment as well as helping with the choice of therapy.

Figure 4. Responses to 2-week treatment with tacrolimus. Data represent values of individual patients and group mean ± SD values. A. Expression of P-glycoprotein on CD4 and CD19 lymphocytes of patients with treatment-resistant RA. B. C/M ratio of peripheral blood mononuclear cells (PBMC) from patients with treatment-resistant RA. C. C/M ratio measured in PBMC of patients with RA before and after 2-week tacrolimus treatment. D. Expression of P-glycoprotein on CD4 lymphocytes of patients with RA before and after 2-week tacrolimus treatment. *p < 0.05, **p < 0.01, Wilcoxon test; ns: nonsignificant.
Table 2. Multivariate logistic analysis of factors involved in response of patients with RA to tacrolimus treatment.

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Estimate</th>
<th>SE</th>
<th>Chi-square</th>
<th>Pr &gt; z</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>0.1069</td>
<td>2.29120</td>
<td>0.00</td>
<td>0.9628</td>
</tr>
<tr>
<td>C/M ratio</td>
<td>9.0576</td>
<td>4.44129</td>
<td>4.16</td>
<td>0.0414</td>
</tr>
<tr>
<td>P-glycoprotein expression on CD4+ lymphocyte</td>
<td>-0.0133</td>
<td>0.00609</td>
<td>4.79</td>
<td>0.0286</td>
</tr>
<tr>
<td>CRP</td>
<td>-0.1996</td>
<td>0.24054</td>
<td>0.69</td>
<td>0.4066</td>
</tr>
<tr>
<td>MS</td>
<td>0.00149</td>
<td>0.001593</td>
<td>0.88</td>
<td>0.3490</td>
</tr>
</tbody>
</table>

C/M: cell/medium; CRP: C-reactive protein; MS: morning stiffness.

Figure 4. Continued.
REFERENCES